Precise engineering of Cisplatin prodrug into supramolecular nanoparticles: Enhanced on in vitro antiproliferative activity and treatment and care of in vivo renal injury

Abstract

Renal cell carcinoma (RCC) is a widespread type of urological tumor that derives from the highly heterogeneous epithelium of the kidney tissue. For the past decade, the treatment of kidney cancer cells has changed clinical care for RCC. Herein, we present a very easy and cost-effective method that incorporates tumor-specific targeting supramolecular nanoassembly, and therapeutically to overcome the different challenges raised by the distribution of the pharmaceutical potential anticancer drug Cisplatin (CIS-PT). On covalent conjugations of hydrophobic linoleic acid by carboxylic group, the CIS-PT prodrugs were skilled in impulsively nanoassembly into extremely steady nanoparticles size (∼100 nm). Electron microscopic techniques have verified the newly synthesized morphology of CIS-PT-NPs. The anticancer properties of CIS-PT and CIS-PT-NPs against Caki-1 and A-498 (renal carcinoma) cancer cell lines have been evaluated after successful synthesis. Other research, such as dual staining acridine orange/ethidium bromide (AO–EB), Hoechst 33,344 and flow cytometry study on the apoptosis mechanisms, have shown that proliferation in renal cancer cells is associated with apoptosis. Further the In vivo toxicity results displays the CIS-PT-NPs remarkably alleviated the toxicity of the potential anticancer drug CIS-PT In vivo while conserving the Pharmaceutical activity. Compared to CIS-PT, CIS-PT-NPs demonstrate excellent In vitro and In vivo property, this study clarified the CIS-PT-NPs as a healthy and positive RCC care chemotherapeutics technique and deserve further clinical evaluations.